



(86) Date de dépôt PCT/PCT Filing Date: 1998/04/22
 (87) Date publication PCT/PCT Publication Date: 1998/12/03
 (45) Date de délivrance/Issue Date: 2008/01/29
 (85) Entrée phase nationale/National Entry: 1999/11/18
 (86) N° demande PCT/PCT Application No.: US 1998/007776
 (87) N° publication PCT/PCT Publication No.: 1998/053811
 (30) Priorité/Priority: 1997/05/27 (US08/863,513)

(51) Cl.Int./Int.Cl. *A61K 38/13* (2006.01),
A61K 31/337 (2006.01), *A61P 37/08* (2006.01)
 (72) Inventeurs/Inventors:
BRODER, SAMUEL, US;
DUCHIN, KENNETH L., US;
SELIM, SAMI, US
 (73) Propriétaire/Owner:
BAKER NORTON PHARMACEUTICALS, INC., US
 (74) Agent: SIM & MCBURNEY

(54) Titre : METHODES ET COMPOSITIONS D'ADMINISTRATION DE TAXANES PAR VOIE ORALE A DES HUMAINS
 (54) Title: METHOD AND COMPOSITIONS FOR ADMINISTERING TAXANES ORALLY TO HUMAN PATIENTS

(57) **Abrégé/Abstract:**

Taxane antineoplastic agents which have heretofore exhibited poor or non-existent oral bioavailability are administered orally to human patients suffering from taxane-responsive disease conditions and made sufficiently bioavailable to achieve therapeutic blood levels. In a preferred embodiment, the taxane, preferably paclitaxel, is co-administered to the patient with an oral cyclosporin enhancing agent, preferably cyclosporin A. By one preferred method, a dose of oral enhancer is administered about 0.5-72 hours before the taxane and a second dose of the enhancer and administered immediately before, together with or immediately after the taxane. A method of treating human patients suffering from taxane-responsive disease conditions is also provided, as well as a method for providing such treatment while preventing or reducing hypersensitivity and allergic reactions without the need for pre-medication.

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|---|
| (51) International Patent Classification⁶ : A61K 31/335 | A1 | (11) International Publication Number: WO 98/53811 (43) International Publication Date: 3 December 1998 (03.12.98) |
| (21) International Application Number: PCT/US98/07776 (22) International Filing Date: 22 April 1998 (22.04.98) (30) Priority Data: 08/863,513 27 May 1997 (27.05.97) US (71) Applicant: BAKER NORTON PHARMACEUTICALS, INC. [US/US]; 4400 Biscayne Boulevard, Miami, FL 33137 (US). (72) Inventors: BRODER, Samuel; 2532 Eagle Run Circle, Weston, FL 33327 (US). DUCHIN, Kenneth, L.; 2679 Cypress Lane, Fort Lauderdale, FL 33332 (US). SELIM, Sami; 17 Colonial, Irvine, CA 92720 (US). (74) Agent: SCHIFFMILLER, Martin, W.; Kirschstein, Ottinger, Israel & Schiffmiller, P.C., 551 Fifth Avenue, New York, NY 10176 (US). | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> |
| (54) Title: METHOD AND COMPOSITIONS FOR ADMINISTERING TAXANES ORALLY TO HUMAN PATIENTS | | |
| (57) Abstract Taxane antineoplastic agents which have heretofore exhibited poor or non-existent oral bioavailability are administered orally to human patients suffering from taxane-responsive disease conditions and made sufficiently bioavailable to achieve therapeutic blood levels. In a preferred embodiment, the taxane, preferably paclitaxel, is co-administered to the patient with an oral cyclosporin enhancing agent, preferably cyclosporin A. By one preferred method, a dose of oral enhancer is administered about 0.5-72 hours before the taxane and a second dose of the enhancer and administered immediately before, together with or immediately after the taxane. A method of treating human patients suffering from taxane-responsive disease conditions is also provided, as well as a method for providing such treatment while preventing or reducing hypersensitivity and allergic reactions without the need for pre-medication. | | |

**METHOD AND COMPOSITIONS FOR ADMINISTERING
TAXANES ORALLY TO HUMAN PATIENTS**

BACKGROUND OF THE INVENTION

The invention relates to methods and compositions for orally administering
5 to human patients pharmaceutical agents that are poorly absorbed from the
gastrointestinal tract, and to methods of treatment of patients through the oral
administration of such agents. One principal aspect of the invention relates to methods
and compositions for orally administering paclitaxel and related taxanes to human
patients.

10 Many valuable pharmacologically active compounds cannot be effectively
administered by the oral route to human patients because of poor or inconsistent
systemic absorption from the gastrointestinal tract. All these pharmaceutical agents
are, therefore, generally administered via intravenous routes, requiring intervention by
a physician or other health care professional, entailing considerable discomfort and
15 potential local trauma to the patient and even requiring administration in a hospital
setting with surgical access in the case of certain IV infusions.

One of the important classes of cytotoxic agents which are not normally
bioavailable when administered orally to humans are the taxanes, which include
paclitaxel, its derivatives and analogs. Paclitaxel (currently marketed as TAXOL[®] by
20 Bristol-Myers Squibb Oncology Division) is a natural diterpene product isolated from the
Pacific yew tree (Taxus brevifolia). It is a member of the taxane family of terpenes. It
was first isolated in 1971 by Wani et al. (J. Am. Chem. Soc., 93:2325, 1971), who
characterized its structure by chemical and X-ray crystallographic methods. One
mechanism for its activity relates to paclitaxel's capacity to bind tubulin, thereby

inhibiting cancer cell growth. Schiff et al., Proc. Natl. Acad. Sci. USA, 77:1561-1565 (1980); Schiff et al., Nature, 277:665-667 (1979); Kumar, J. Biol. Chem., 256: 10435-10441 (1981).

Paclitaxel has been approved for clinical use in the treatment of refractory
5 ovarian cancer in the United States (Markman et al., Yale Journal of Biology and Medicine, 64:583, 1991; McGuire et al., Ann. Intern. Med., 111:273, 1989). It is effective for chemotherapy for several types of neoplasms including breast (Holmes et al., J. Nat. Cancer Inst., 83:1797, 1991) and has been approved for treatment of breast cancer as well. It is a potential candidate for treatment of neoplasms in the skin (Einzig
10 et al., Proc. Am. Soc. Clin. Oncol., 20:46), lung cancer and head and neck carcinomas (Forastire et al. Sem. Oncol., 20:56, 1990). The compound also shows potential for the treatment of polycystic kidney disease (Woo et al, Nature, 368:750, 1994) and malaria.

Paclitaxel is only slightly soluble in water and this has created significant problems in developing suitable injectable and infusion formulations useful for
15 anticancer chemotherapy. Some formulations of paclitaxel for IV infusion have been developed utilizing CREMOPHOR EL™ (polyethoxylated castor oil) as the drug carrier because of paclitaxel's aqueous insolubility. For example, paclitaxel used in clinical testing under the aegis of the NCI has been formulated in 50% CREMOPHOR EL™ and 50% dehydrated alcohol. CREMOPHOR EL™ however, when administered
20 intravenously, is itself toxic and produces vasodilation, labored breathing, lethargy, hypotension and death in dogs. It is also believed to be at least partially responsible for the allergic-type reactions observed during paclitaxel administration, although there is some evidence that paclitaxel may itself provoke acute reactions even in the absence of Cremophor.

In an attempt to increase paclitaxel's solubility and to develop more safe clinical formulations, studies have been directed to synthesizing paclitaxel analogs where the 2' and/or 7-position is derivatized with groups that would enhance water solubility. These efforts have yielded prodrug compounds that are more water soluble than the parent compound and that display the cytotoxic properties upon activation. One important group of such prodrugs includes the 2'-onium salts of paclitaxel and docetaxel, particularly the 2'-methylpyridinium mesylate (2'-MPM) salts.

Paclitaxel is very poorly absorbed when administered orally (less than 1%); see Eiseman et al., Second NCI Workshop on Taxol and Taxus (Sept. 1992); Suffness et al. in Taxol Science and Applications (CRC Press 1995). Eiseman et al. indicate that paclitaxel has a bioavailability of 0% upon oral administration, and Suffness et al. report that oral dosing with paclitaxel did not seem possible since no evidence of antitumor activity was found on oral administration up to 160 mg/kg/day. Moreover, no effective method has been developed to enable the effective administration of oral paclitaxel (i.e., a method of increasing the oral bioavailability of paclitaxel) or of other oral taxanes or paclitaxel analogs such as docetaxel which exhibit antitumor activity. For this reason, paclitaxel has not until now been administered orally to human patients, and certainly not in the course of treating paclitaxel-responsive diseases.

Docetaxel (N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyl paclitaxel) has become commercially available as TAXOTERE[®] (Rhone-Poulenc-Rorer S.A.) in parenteral form for the treatment of breast cancer. To date no reference has been made in the scientific literature to oral absorption of docetaxel in animals or patients.

It has been speculated that, in some cases, the poor or non-existent bioavailability of a drug such as paclitaxel after oral administration is a result of the

activity of a multidrug transporter, a membrane-bound P-glycoprotein, which functions as an energy-dependent transport or efflux pump to decrease intracellular accumulation of drug by extruding xenobiotics from the cell. This P-glycoprotein has been identified in normal tissues of secretory endothelium, such as the biliary lining, brush border of the proximal tubule in the kidney and luminal surface of the intestine, and vascular endothelial cells lining the blood brain barrier, placenta and testis.

It is believed that the P-glycoprotein efflux pump prevents certain pharmaceutical compounds from transversing the mucosal cells of the small intestine and, therefore, from being absorbed into the systemic circulation. A number of known non-cytotoxic pharmacological agents have been shown to inhibit P-glycoprotein, including cyclosporin A (also known as cyclosporine), verapamil, tamoxifen, quinidine and phenothiazines, among others. Many of these studies were aimed at achieving greater accumulation of intravenously administered cytotoxic drugs inside tumor cells. In fact, clinical trials have been conducted to study the effects of cyclosporine on the pharmacokinetics and toxicities of paclitaxel (Fisher et al., Proc. Am. Soc. Clin. Oncol., 13: 143, 1994); doxorubicin (Bartlett et al., J. Clin. Onc. 12:835-842, 1994); and etoposide (Lum et al., J. Clin. Onc. 10:1635-42, 1992), all of which are anti-cancer agents known to be subject to multidrug resistance (MDR). These trials showed that patients receiving intravenous cyclosporine prior to or together with the anti-cancer drugs had higher blood levels of those drugs, presumably through reduced body clearance, and exhibited the expected toxicity at substantially lower dosage levels. These findings tended to indicate that the concomitant administration of cyclosporine suppressed the MDR action of P-glycoprotein, enabling larger intracellular accumulations of the therapeutic agents. For a general discussion of the

pharmacologic implications for the clinical use of P-glycoprotein inhibitors, see Lum et al., Drug Resist. Clin. Onc. Hemat., 9: 319-336 (1995); Schinkel et al., Eur. J. Cancer, 31A: 1295-1298 (1995).

In the aforescribed studies relating to the use of cyclosporine to increase the blood levels of pharmaceutical agents, the active anti-tumor agents and the cyclosporine were administered intravenously. No suggestion was made in these publications that cyclosporine could be orally administered to substantially increase the bioavailability of orally administered anti-cancer drugs and other pharmaceutical agents which are themselves poorly absorbed from the gut without producing highly toxic side effects. Indeed, in the 1995 review paper cited above, Lum et al. showed that concomitant IV administration of MDR inhibitors and chemotherapeutic agents subject to MDR increased toxicity levels and exacerbated the patients' serious side effects. Schinkel et al. briefly adverted to the fact that MDR1 and P-glycoprotein are abundant in the mucosal cells of the intestine, and that this may affect the oral bioavailability of P-glycoprotein substrate drugs, but did not suggest or imply that the oral administration of MDR suppressing agents could improve the bioavailability of the orally unavailable agents. Furthermore, like Lum et al., Schinkel et al. warned that P-glycoprotein inhibitors can dramatically increase toxicity in chemotherapy patients and should, therefore, be used cautiously.

In an earlier publication, Schinkel et al. showed that absorption of orally ingested ivermectin was increased in mice homozygous for a disruption of the MDR1 gene in comparison with normal mice, demonstrating that P-glycoprotein played a major role in reducing the bioavailability of this agent (Cell, 77: 491-502, 1994). In

addition, this study also showed that the penetration of vinblastine into various tissues was enhanced in the mutant mice.

None of the published studies provided any regimen for implementing the effective oral administration to humans of poorly bioavailable drugs such as paclitaxel, e.g., indicating the respective dosage ranges and timing of administration for specific target drugs and bioavailability-enhancing agents are best suited for promoting oral absorption of each target drug or class of drugs.


Methods disclosed in the art for increasing gut absorption of drugs that have until now only been administered parenterally generally focus on the use of permeation and solubility enhancers as promoting agents, or the co-administration by intraluminal perfusion in the small intestine or by the intravenous route of P-glycoprotein inhibitors, e.g., Leu et al., Cancer Chemother. Pharmacol., 35: 432-436, 1995 (perfusion or IV infusion of quinidine suppresses efflux of etoposide into the lumen of the G.I. tract from the blood). But these methods suffer from numerous drawbacks. The solubility and permeability enhancing agents are often either impractical or ineffective for oral administration in the doses required and may interfere with the pharmacological activity of the target drug. Parenteral administration of P-glycoprotein inhibitors in therapeutic (or near-therapeutic) doses into humans can cause severe clinical consequences. In the case of quinidine, for example, IV administration may cause arrhythmias, peripheral vasodilation, gastrointestinal upset and the like. Most important, they do not teach how to administer any anti-tumor agents orally to human beings.

In published PCT application WO 95/20980 (published August 10, 1995) Benet et al. disclose a purported method for increasing the bioavailability of orally

administered hydrophobic pharmaceutical compounds. This method comprises orally administering such compounds to the patient concurrently with a bioenhancer comprising an inhibitor of a cytochrome P450 3A enzyme or an inhibitor of P-glycoprotein-mediated membrane transport. Benet et al.,
5 however, provide virtually no means for identifying which bioavailability enhancing agents will improve-the availability of specific "target" pharmaceutical compounds, nor do they indicate specific dosage amounts, schedules or regimens for administration of the enhancing or target agents. In fact, although the Benet application lists dozens of potential enhancers (P450
10 3A inhibitors) and target drugs (P450 3A substrates), the only combination of enhancer and target agent supported by any experimental evidence in the application is ketoconazole as the enhancer and cyclosporin A as the target drug.

When describing the general characteristics of compounds which can
15 be used as bioenhancers by reduction of P-glycoprotein transport activity, Benet et al. indicate that these are hydrophobic compounds which generally, but not necessarily, comprise two co-planar aromatic rings, a positively charged nitrogen group or a carbonyl group - a class that includes an enormous number of compounds, most of which would not provide the
20 desired absorption enhancing activity in the case of specific target agents. Moreover, the classes of target agents disclosed by Benet et al. include the great majority of pharmaceutical agents listed in the Physicians' Desk Reference, 51st Edition, Medical Economics Company, 1997. These inclusion criteria are of no value to medical practitioners seeking safe, practical
25 and effective methods of orally administering specific pharmaceutical agents.

A further deficiency with Benet et al.'s disclosure is the standard applied for determining whether bioavailability of a drug that is poorly absorbed upon oral administration has been improved. Benet et al. indicate that any P-glycoprotein _____



inhibiting agent which, when present in the gut at a given concentration, reduces transmembranal transport of Rhodamine 123 by P-glycoprotein in brush border membrane vesicles or P-glycoprotein containing cells by 10% or more may be considered a bioenhancing agent at that concentration and can be used in the practice
5 of their invention. But an increase of only 10% in absorption from the gut of an otherwise not absorbable agent is inadequate to render the agent therapeutically valuable for any purpose. Indeed, under guidelines of the Federal Food and Drug Administration, two pharmaceutical formulations containing the same active ingredient, but differing in their bioavailability levels by -20%/+25%, are still considered
10 bioequivalent because for most drugs a -20%/+25% difference in concentration of the active ingredient in the blood is not clinically significant. Approved Drug Products with Therapeutic Equivalence Evaluations (Dept. of HHS, 14th ed. 1994). When the FDA rules that two pharmaceutical formulations are bioequivalent, physicians and pharmacists consider them freely substitutable for one another.

15 In general, Benet et al. provides no teaching that could be followed by persons skilled in the medical and pharmaceutical arts to identify suitable bioenhancer/target drug combinations or to design specific treatment regimens and schedules which would render the target agents therapeutically effective upon oral administration to human patients. Benet et al. also provides no direction whatsoever
20 regarding how paclitaxel and other taxanes might be administered orally to humans with therapeutic efficacy and acceptable toxicity.

Thus, a safe yet effective method for increasing the systemic availability upon oral administration to human patients of drugs that are currently administered only

parenterally because they are not absorbed sufficiently or consistently when administered by the oral route is required, and has not been provided in the prior art.

Surprisingly, it has now been discovered and experimentally verified that the taxane class of antineoplastic agents, particularly paclitaxel, can be orally administered to human beings with substantial and therapeutic blood levels being achieved, and with no undue toxicity or adverse side effects observed even without pre-administration of medications to prevent adverse reactions.

The present invention relates in its principal aspect to the oral administration of one or a combination of taxanes to human patients suffering from disease conditions responsive to those agents. A preferred embodiment of the invention is a method of increasing the oral bioavailability in humans of taxanes, which are poorly absorbed or not absorbed at all from the gastrointestinal tract or gut, by pre-administering and/or simultaneously administering to a human subject by the oral route one or a combination of agents ("enhancing agents") effective in inhibiting cellular multi-drug resistance. If pre-administration is used, the bioavailability enhancing agent or agents must be administered in sufficient quantities and within a short enough time period before administration of the taxane whose bioavailability is to be increased (the "target drug" or "target agent") so that a sufficient level of the enhancing agent remains at the site of absorption at the time of administration of the target agent to effectively suppress the activity of the multi-drug transporter substances, metabolic enzymes and/or other factors which prevent or inhibit gut absorption of the target agent.

A second aspect or embodiment of the invention pertains to a method of treating patients suffering from taxane-responsive diseases through the oral administration of taxanes that were heretofore available by parenteral administration

only. Yet another aspect or embodiment is a method of preventing or reducing hypersensitivity and allergic reactions in patients receiving taxane therapy.

According to another aspect of the invention, there is provided an oral administration of a taxane to a human patient suffering from a taxane-
5 responsive disease condition, the taxane being administered in an amount effective to treat said condition.

According to yet another aspect of the invention, there is provided an oral administration of paclitaxel to a human patient suffering from a paclitaxel-
10 responsive disease condition, the paclitaxel being administered in an amount effective to treat said condition.

According to a further aspect of the invention, there is provided an oral administration of docetaxel to a human patient suffering from a docetaxel-
15 responsive disease condition, the docetaxel being administered in an amount effective to treat said condition.

According to a further aspect of the present invention, there is provided
an oral administration to a human patient of a derivative, analog or prodrug of
paclitaxel or docetaxel to treat a disease condition responsive to the
derivative, analog or prodrug, the derivative, analog or prodrug being
20 administered in an amount effective to treat the condition.

According to a further aspect of the present invention, there is provided
a method of making an orally administered taxane bioavailable to human
patients at a level sufficient to treat taxane-responsive disease conditions, the
method comprising the oral co-administration to the patient of an effective
disease-treating amount of the taxane together with an effective amount of an
25 oral bioavailability-enhancing agent selected from the group consisting of
cyclosporins A through Z, (Me-Ile-4)-cyclosporin, dihydro cyclosporin A,
dihydro cyclosporin C, acetyl cyclosporin A.

According to a further aspect of the present invention, there is provided
a method of treating a human patient suffering from a taxane-responsive
30 disease condition, the method comprising the oral administration of an
effective disease-treating amount of a taxane to the patient.

According to yet a further aspect of the present invention, there is
provided a method of preventing or reducing hypersensitivity and allergic
reactions in human patients receiving taxane therapy for taxane-responsive

10a

disease conditions, the method comprising the oral administration of the taxane to the patient.

According to an aspect of the invention, there is provided, use of a cyclosporin as an oral bioavailability enhancing agent in the preparation of a medicament for making an orally administrable taxane bioavailable to a patient at a level sufficient to treat taxane-responsive disease conditions, wherein the cyclosporin is capable of being orally co-administered to the patient with a taxane.

According to another aspect of the invention, there is provided, use of an oral bioavailability enhancing agent in the preparation of a medicament for preventing or reducing hypersensitivity or allergic reactions in a patient undergoing taxane therapy for a taxane-responsive disease condition, wherein a taxane and an oral bioavailability enhancing agent are capable of being orally co-administered to the patient, without prior administration of medication to prevent the hypersensitivity or allergic reactions, and wherein the taxane reaches therapeutic blood or plasma levels in said patient.

According to another aspect of the invention, there is provided, use of a cyclosporin as an oral bioavailability enhancing agent wherein the cyclosporin is capable of being orally co-administered for the treatment of taxane-responsive disease conditions with a taxane in a patient.

According to a further aspect of the invention, there is provided, use of an oral bioavailability enhancing agent for the treatment, prevention or reduction of hypersensitivity or allergic reactions in a patient undergoing taxane therapy for a taxane-responsive disease condition, wherein a taxane and an oral bioavailability enhancing agent are capable of being orally co-administered without prior administration of medication to prevent the hypersensitivity or allergic reactions, and wherein the taxane reaches therapeutic blood or plasma levels in said patient.

According to another aspect of the invention, there is provided, use of an oral bioavailability enhancing agent for the prevention or reduction of hypersensitivity or allergic reactions in a patient undergoing taxane therapy for a taxane-responsive disease condition, wherein a taxane and an oral bioavailability enhancing agent are capable of being orally co-administered without prior administration of medication to prevent the hypersensitivity or allergic reactions, and wherein the taxane reaches therapeutic blood or plasma levels in said patient.

10b

According to a further aspect of the invention, there is provided, use of a taxane and an oral bioavailability-enhancing agent for the manufacture of a medicament for oral co-administration of the taxane and the oral bioavailability-enhancing agent to a patient to provide the patient with taxane therapy for the treatment of a taxane-responsive disease, wherein the patient is a human to whom there has been no prior administration of medication to prevent hypersensitivity or allergic reactions to the taxane therapy.

FIG. 1 is a graph reflecting the circulating levels of paclitaxel in samples taken: (a) lowercurve - over a period of 6-8 hours from one group of rats administered only oral paclitaxel, and (b) upper curve - over a period of 24 hours from a second group of rats administered orally one hour prior to the co-administration of oral cyclosporin A and oral paclitaxel.

FIG. 2 is a graph reflecting the levels of paclitaxel in plasma samples from a human patient administered oral paclitaxel after two doses of oral cyclosporin A, the first administered one hour before the paclitaxel dose and the second administered immediately before the paclitaxel.

FIG. 3 is graph reflecting the levels of paclitaxel in plasma samples from a second human patient administered oral paclitaxel by the same regimen as described with respect to FIG. 2.

FIG. 4 is a graph reflecting a comparison of the paclitaxel plasma level curves determined over 24 hours in rats (FIG.1) and in humans (FIGS. 2 and 3) administered oral paclitaxel after two doses of oral cyclosporin A.

The present invention pertains in its principal aspect to the oral administration of the taxane class of antineoplastic agents, in particular paclitaxel and its derivatives, analogs and prodrugs, and the semi-synthetic paclitaxel analog docetaxel (N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyl paclitaxel), to human patients suffering from taxane-responsive disease conditions. The preferred embodiments or aspects of the invention include (a) methods for oral administration of taxanes heretofore administered only parenterally with sufficient bioavailability to achieve therapeutic blood-levels; (b) methods

of treating human patients suffering from taxane-responsive disease conditions through the oral administration of taxanes; and (c) methods of preventing or reducing hypersensitivity and allergic reaction in patients receiving taxane therapy.

The term "bioavailability" as used herein refers to the systemic availability (i.e.,
5 blood/plasma levels) of a given amount of drug administered to a patient.

It has now been discovered that the taxanes, which have poor oral absorption profiles, can be administered orally to humans with sufficient systemic absorption and oral bioavailability achieved to exhibit plasma levels in the therapeutic range. In fact, we have actually administered the taxane paclitaxel orally to human patients suffering from
10 cancers and have verified that therapeutic blood levels of paclitaxel were achieved in these patients over extended periods of time.

We have observed in animal studies that certain agents such as cyclosporin A, when administered orally immediately after and/or before drugs such as paclitaxel, increase absorption of the latter drugs from the gut to an unexpected and surprising
15 degree resulting in therapeutic levels being achieved. It is not at all clear, however, that these observed results are due to the suppression of the P-glycoprotein pump.

It is emphasized that the present invention is not limited to the use of any particular oral bioavailability-enhancing agents for co-administration with an oral taxane to make the latter bioavailable to human patients. The invention resides broadly in the
20 oral administration of taxanes to human patients, and is not restricted to any specific enhancers, dosage amounts or regimens or the utilization of particular biological mechanisms or pharmaceutical techniques to make the taxanes available for oral administration to humans.

The preferred embodiment of the method of the invention for oral administration to humans of paclitaxel, its derivatives, analogs and prodrugs, and other taxanes comprises the oral administration of an oral absorption or bioavailability enhancing agent to a human patient simultaneously with, or prior to, or both simultaneously with and prior to the oral administration to increase the quantity of absorption of the intact target agent into the bloodstream.

The orally administered enhancing agents which may be used in practicing the preferred embodiment of the invention include, but are not limited to, the following:

10 Cyclosporins, including cyclosporins A through Z but particularly cyclosporin A (cyclosporine), cyclosporin F, cyclosporin D, dihydro cyclosporin A, dihydro cyclosporin C, acetyl cyclosporin A, PSC-833, SDZ-NIM 811¹ (both from Sandoz Pharmaceutical Corp). The structures of cyclosporins A-Z are described in Table 1 below.

15 The class of orally administered target therapeutic agents whose oral absorption is increased by the enhancing agents includes, but is not limited to, the following:

20 Paclitaxel, other taxanes, docetaxel and derivatives and prodrugs of all of the foregoing, particularly their 2'-MPM salts and other 2'-methylpyridinium salts.

¹SDZ-NIM 811 is (Me-Ile-4)-cyclosporin, an antiviral, non-immunosuppressive cyclosporin.

TABLE 1**Cyclosporins A-Z**

| Cyclosporin | Amino Acids | | | | | | | | | | |
|-------------|-----------------------------|-----|-----|-------|-----|-------|-----|-------|-------|-------|-------|
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 5 Cy- | | | | | | | | | | | |
| CyA | Mebmt | Abu | Sar | MeLeu | Val | MeLeu | Ala | D-Ala | MeLeu | MeLeu | MeVal |
| CyB | Mebmt | Ala | Sar | MeLeu | Val | MeLeu | Ala | D-Ala | MeLeu | MeLeu | MeVal |
| CyC | Mebmt | Thr | Sar | MeLeu | Val | MeLeu | Ala | D-Ala | MeLeu | MeLeu | MeVal |
| CyD | Mebmt | Val | Sar | MeLeu | Val | MeLeu | Ala | D-Ala | MeLeu | MeLeu | MeVal |
| 10 CyE | Mebmt | Abu | Sar | MeLeu | Val | MeLeu | Ala | D-Ala | MeLeu | MeLeu | Val |
| CyF | Desoxy-Mebmt | Abu | Sar | MeLeu | Val | MeLeu | Ala | D-Ala | MeLeu | MeLeu | MeVal |
| CyG | Mebmt | Nva | Sar | MeLeu | Val | MeLeu | Ala | D-Ala | MeLeu | MeLeu | MeVal |
| CyH | Mebmt | Abu | Sar | MeLeu | Val | MeLeu | Ala | D-Ala | MeLeu | MeLeu | D-Mev |
| CyI | Mebmt | Val | Sar | MeLeu | Val | MeLeu | Ala | D-Ala | MeLeu | Leu | MeVal |
| 15 CyK | Desoxy-Mebmt | Val | Sar | MeLeu | Val | MeLeu | Ala | D-Ala | MeLeu | MeLeu | MeVal |
| CyL | Bmt | Abu | Sar | MeLeu | Val | MeLeu | Ala | D-Ala | MeLeu | MeLeu | MeVal |
| CyM | Mebmt | Nva | Sar | MeLeu | Val | MeLeu | Ala | D-Ala | MeLeu | MeLeu | MeVal |
| CyN | Mebmt | Nva | Sar | MeLeu | Val | MeLeu | Ala | D-Ala | MeLeu | Leu | MeVal |
| CyO | MeLeu | Nva | Sar | MeLeu | Val | MeLeu | Ala | D-Ala | MeLeu | MeLeu | MeVal |
| 20 CyP | Bmt | Thr | Sar | MeLeu | Val | MeLeu | Ala | D-Ala | MeLeu | MeLeu | MeVal |
| CyQ | Mebmt | Abu | Sar | Val | Val | MeLeu | Ala | D-Ala | MeLeu | MeLeu | MeVal |
| CyR | Mebmt | Abu | Sar | MeLeu | Val | Leu | Ala | D-Ala | MeLeu | Leu | MeVal |
| CyS | Mebmt | Thr | Sar | Val | Val | MeLeu | Ala | D-Ala | MeLeu | MeLeu | MeVal |
| CyT | Mebmt | Abu | Sar | MeLeu | Val | MeLeu | Ala | D-Ala | MeLeu | Leu | MeVal |
| 25 CyU | Mebmt | Abu | Sar | MeLeu | Val | Leu | Ala | D-Ala | MeLeu | MeLeu | MeVal |
| CyV | Mebmt | Abu | Sar | MeLeu | Val | MeLeu | Ala | D-Ala | MeLeu | MeLeu | MeVal |
| CyW | Mebmt | Thr | Sar | MeLeu | Val | MeLeu | Ala | D-Ala | MeLeu | MeLeu | Val |
| CyX | Mebmt | Nva | Sar | MeLeu | Val | MeLeu | Ala | D-Ala | Leu | MeLeu | MeVal |
| CyY | Mebmt | Nva | Sar | MeLeu | Val | Leu | Ala | D-Ala | MeLeu | MeLeu | MeVal |
| 30 CyZ | MeAmino- n-octyl acid | Abu | Sar | MeLeu | Val | MeLeu | Ala | D-Ala | MeLeu | MeLeu | MeVal |

Cyclosporins are a group of nonpolar cyclic oligopeptides (some of which have immunosuppressant activity) produced by the genus Topycladium, including, e.g., Topycladium inflatum Gams (formerly designated as Trichoderma polysporum), Topycladium terricola and other fungi imperfecti. The major component, cyclosporin A (cyclosporine or CsA), has been identified along with several other lesser metabolites, for example, cyclosporins B through Z, some of which exhibit substantially less immunosuppressive activity than cyclosporin A. A number of synthetic and semi-synthetic analogs have also been prepared. See generally Jegorov et al., Phytochemistry, 38: 403-407 (1995). The present invention comprehends natural, semi-synthetic and synthetic analogs of cyclosporins.

Cyclosporins are neutral, lipophilic, cyclic undecapeptides with molecular weights of about 1200. They are used intravenously or orally as immunosuppressants, primarily for organ transplantation and certain other conditions. Cyclosporins, particularly cyclosporine (cyclosporin A), are known inhibitors of the P-glycoprotein efflux pump and other transporter pumps as well as of certain P450 degradative enzymes, but to date no effective regimens for applying this property clinically have been developed to the point of clinical and commercial feasibility or regulatory approval.

One of the surprising discoveries of the invention is that the immunosuppression observed with certain cyclosporins is not inextricably linked to improvement in oral bioavailability of therapeutic agents. Thus, cyclosporin F enhances the oral bioavailability of paclitaxel even though, according to reports in the literature, it does not display immunosuppressive activity. Stewart et al.,

Transplantation Proceedings, 20:(Supp. 3) 989-992 (1988); Granelli-Piperno et al.,
Transplantation, 46:53S-60S (1988).

Another possible explanation for the observed increased bioavailability of paclitaxel is that there may be interaction at the level of the drug metabolizing enzymes for cyclosporine and paclitaxel. It is known that both agents are highly metabolized by the cytochrome P-450 system (e.g., P-450 3A), which is concentrated in the liver as well as the small intestine. It is conceivable that cyclosporine which was administered first may have inhibited these enzymes so that paclitaxel, which is non-polar and lipophilic, could be absorbed. In the absence of this local inhibition, paclitaxel would be metabolized to more polar metabolites which would not transverse the mucosal cells.

This theorized inhibition of gut metabolism of the target agent might have little or no effect in increasing systemic blood levels when the target agent is administered intravenously. Moreover, since the primary effect of the oral absorption enhancing agent may be a local effect in the gut lumen, doses which are subtherapeutic (e.g., in terms of immunosuppression) should be effective in achieving the desired effect. This is an important consideration in the case of enhancing agents such as cyclosporins which have powerful immunosuppressant activity and can present toxicity problems if administered at high dose levels. Our observation that non-immunosuppressive cyclosporins, such as cyclosporin F, can still function as an oral enhancer is of great clinical value.

It is important to note that while we provide hypotheses as to the mechanisms of action which underlie our invention, we do not actually know the

mechanism(s) responsible for the surprising findings discussed herein; and this does not impede one of skill in the art from practicing the invention described. It may well be that none of the suggested mechanisms, some of them, or all of them play a part in the experimentally and clinically verified enhancement of taxane (specifically paclitaxel) oral bioavailability.

The dosage range of the enhancing agent to be co-administered with the target agent in accordance with the invention is about 0.1 to about 20 mg/kg of patient body weight. "Co-administration" of the enhancing agent comprehends administration substantially simultaneously with the target agent (either less than 0.5 hr. before, less than 0.5 hr. after or together), from about 0.5 to about 72 hr. before the administration of the target agent, or both, i.e., with one or more doses of the same or different enhancing agents given at least 0.5 hr. before and one dose given substantially simultaneously with (either together with or immediately before or after) the target agent. Additionally, "co-administration" comprehends administering more than one dose of target agent within 72 hr. after a dose of enhancing agent, in other words, the enhancing agent(s) need not be administered again before or with every administration of target agent, but may be administered intermittently during the course of treatment.

The dosage range of orally administered taxane target agents will vary from compound to compound based on its therapeutic index, the requirements of the condition being treated, the status of the subject and so forth. The method of the invention makes it possible to administer paclitaxel and other taxanes orally ranging from about 20 mg/m² to about 1000 mg/m² (based on patient body surface area) or

about 2-30 mg/kg (based on patient body weight) as single or divided (2-3) daily doses, and maintain the plasma levels of paclitaxel in humans in the range of 50-500 ng/ml for extended periods of time (e.g., 8-12 hours) after each oral dose. These levels are at least comparable to those achieved with 96-hour IV infusion taxol therapy (which causes the patient great inconvenience, discomfort, loss of quality time, infection potential, etc.). Moreover, such plasma levels of paclitaxel are more than sufficient to provide the desired pharmacological activities of the target drug, e.g., inhibition of tubulin disassembly (which occurs at levels of about 0.1 μ M, or about 85 ng/ml) and inhibition of protein isoprenylation (which occurs at levels of about 0.03 μ M, or about 25 ng/ml) which are directly related to its antitumor effects by inhibiting oncogene functions and other signal-transducing proteins that play a pivotal role in cell growth regulation.

Preferred oral dosage amounts for paclitaxel and other taxanes administered according to the invention are about 50-200 mg/m² or about 2-6 mg/kg.

It may be suitable in some instances to administer to the patient a higher initial loading dose of the target agent to achieve peak blood levels, followed by lower maintenance doses.

Two or more different enhancing agents and/or two or more different target agents may be administered together, alternately or intermittently in all of the various aspects of the method of the invention.

The present invention also comprehends methods of treating human patients afflicted with cancers, tumors, Kaposi's sarcoma, malignancies, uncontrolled tissue or cellular proliferation secondary to tissue injury, and any other disease

conditions responsive to paclitaxel, taxanes, docetaxel, and/or prodrugs and derivatives of all the foregoing such as paclitaxel 2'-MPM, and docetaxel 2'-MPM, with orally administered dosage forms comprising one or more of those agents. Among the types of carcinoma which may be treated particularly effectively with oral paclitaxel, docetaxel, other taxanes, and their prodrugs and derivatives, are hepatocellular carcinoma and liver metastases, cancers of the gastrointestinal tract, pancreas, prostate and lung, and Kaposi's sarcoma. Examples of non-cancerous disease conditions which may be effectively treated with these active agents administered orally in accordance with the present invention are uncontrolled tissue or cellular proliferation secondary to tissue injury, polycystic kidney disease, inflammatory diseases (e.g., arthritis) and malaria, including chloroquine- and pyrimethamine-resistant malaria parasites (Pouvelle et al., J. Clin. Invest., 44: 413-417, 1994).

The antitumor agents which heretofore were administered to human patients only parenterally can now be administered to humans in accordance with the invention by the oral route with sufficient bioavailability to provide pharmacologically active blood concentrations which will be particularly effective in the treatment of patients with primary tumors and metastases. The active ingredients will penetrate the gut wall as a result of the prior and/or concomitant administration of the cyclosporin enhancers and will be taken up by the portal circulation rapidly, providing a higher local initial concentration of the chemotherapeutic agents in the liver (a higher local concentration than is currently achieved with IV infusion therapy) than in the general systemic circulation or in most other organs at one and seven days.

Furthermore, it should be noted that the higher levels of paclitaxel in the liver after oral administration may not be reflected in increased plasma levels because of the high first pass effect of the liver. The method of the invention, in selectively producing high blood concentrations of antitumor agents, is particularly valuable in the treatment of liver cancers (e.g., hepatocellular carcinoma and liver metastases), gastrointestinal cancers (e.g., colon, rectal) and lung cancers.

The plasma levels of the active target agents administered orally with the appropriate enhancing agents as provided in the present invention are remarkably and surprisingly similar to that observed upon IV administration. A series of studies with experimental animals showed that steady state plasma levels of paclitaxel were achieved upon oral co-administration with CsA by the third day of the regimen. The levels of the target agent achieved at steady state were comparable to those achieved in patients by a 96-hour IV infusion of paclitaxel. A 27% response rate was found in taxane-failure patients with metastatic breast cancer treated with a continuous 96-hour infusion every three weeks (Seidman et al., *J. Clin. Oncol.*, 14:1877, 1996). It is believed that similar results can be achieved with the treatment methods of the present invention, without the discomfort, inconvenience and risks of prolonged IV infusions.

The data reflected in FIGS. 1-4 are especially noteworthy and surprising. As described in more detail in the Examples set forth below, the data reflected in FIG. 1 were generated from studies of paclitaxel administration to rats, but the data reflected in FIGS. 2 and 3 reflect actual concentration levels of paclitaxel over time in the plasma of two human patients administered oral paclitaxel in accordance with the

present invention, i.e., with co-administration of an oral cyclosporin enhancing agent. The human data are remarkable not merely because they reflect for the first time, to the extent found in the literature, that paclitaxel was administered orally to human beings requiring paclitaxel therapy, but also
5 because therapeutic-level plasma concentrations were achieved and maintained over about a 24-hour period; indeed, the levels of drug seen in the plasma of the human patients were comparable to the levels achieved upon IV administration and the methods used did not bring about serious local or systemic side effects.

10 Apart from the animal (rat) test data reported in the Examples hereinafter and reflected in FIGS. 1 and 4, we conducted an extensive series of studies in rats wherein paclitaxel and other taxanes were administered orally together with cyclosporin A and other bioavailability enhancing cyclosporins C, D, F and G, and the results of these studies were reported
15 and illustrated in U.S. Patent No. 6,245,805. Moreover, the effects of the oral administration of taxanes, particularly paclitaxet, to animal subjects concomitantly with oral doses of cyclosporins was compared in the parent application with the administration of the same target agents alone, by IV and oral routes, and the administration of other potential but less effective
20 bioavailability enhancing agents together with the target drugs.

It has now been demonstrated that the rat pharmacokinetic profile of paclitaxel co-administered with oral cyclosporin A is quite comparable to the profile in human patients receiving the same regimen. Indeed, FIG. 4 reflects a superimposition

25



on the same graph of the plasma concentration curves for paclitaxel over a 24-hour period following oral co-administration of two doses of enhancer (cyclosporin A) spaced one hour apart with oral paclitaxel administered after the second dose of enhancer, said data being derived from the 24-hour rat study reflected in FIG. 1 and the studies on human patients reflected in FIGS. 2 and 3. It may be observed that the three curves on the graph in FIG. 4 (one rat and two human) are of very similar configuration, indicating that the results in humans are confirmatory of the animal test results.

The current application does not diminish or detract from the importance and relevance of data obtained in the rat. The rat is an accepted model for assessing the pharmacokinetics and absorption profiles of chemotherapeutic agents. However, because of known species-to-species variations, no clinician or medical practitioner could administer paclitaxel or other taxanes orally to humans with confidence based on the animal data alone without any human clinical experience. We have, contrary to conventional wisdom in the art, taught and actually provided a method whereby taxanes can be orally administered safely and effectively to humans. From the standpoint of a physician, the current invention is a vast improvement over the prior art, and teaches that the pharmacologic properties of a taxane such as paclitaxel can be utilized in clinical practice without the requirement for intravenous catheters and time spent in a hospital or chemotherapy clinic, without the attendant expense, inconvenience and risk of infection to the patient, and even without pre-medication to avoid hypersensitivity or allergic reactions, and potential adverse effects from the pre-medications themselves.

Oral dosage forms of the target agents whose bioavailability is increased by the co-administration of the enhancing agents may be in the form of conventional tablets, capsules (softgel or hard gel), caplets, gelcaps, pills, liquids (e.g., solutions, suspensions or elixirs), powders, lozenges, micronized particles or osmotic delivery systems and any other oral dosage forms known in the pharmaceutical arts. The liquid preparations may include, for example, paclitaxel or other taxane in a vehicle comprising CREMOPHOR EL or other polyethoxylated castor oil, alcohol and/or a polyoxyethylated sorbitan mono-oleate (e.g., TWEEN[®] 80, ICI Americas, Inc.) with or without flavoring. Each dosage form includes an effective amount of a taxane target agent and pharmaceutically inert ingredients, e.g., conventional excipients, vehicles, fillers, binders, disintegrants, solvents, solubilizing agents, sweeteners, coloring agents and any other inactive ingredients which are regularly included in pharmaceutical dosage forms for oral administration. Many such dosage forms and oral vehicles immediately after listings of inactive ingredients therefor are set forth in Remington's Pharmaceutical Sciences, 17th edition (1985).

Precise amounts of each of the target drugs in the oral dosage forms will vary depending on the age, weight, disease and condition of the patient. For example, paclitaxel or other taxane dosage forms may contain sufficient quantities of the target agent to provide a daily dosage of about 20-1000 mg/m² (based on patient body surface area) or about 2-30 mg/kg (based on patient body weight) as single or divided (2-3) daily doses. Preferred dosage amounts are about 50-200 mg/m² or about 2-6 mg/kg.

Dosing schedules for the treatment method of the present invention, for example, the treatment of paclitaxel-responsive diseases with oral paclitaxel dosage forms co-administered with enhancing agents, can likewise be adjusted to account for the patient's characteristics and disease status. Preferred dosing schedules for administration of oral paclitaxel are (a) the daily administration to a patient in need thereof of 1-3 equally divided doses providing about 20-1000 mg/m² (based on body surface area), and preferably about 50-200 mg/m², with said daily administration being continued for 1-4 consecutive days each 2-3 weeks, or (b) administration for about one day each week. The former schedule is comparable to use of a 96-hour paclitaxel infusion every 2-3 weeks, which is considered by some a preferred IV treatment regimen.

Oral administration of taxanes in accordance with the invention may actually decrease toxic side effects in many cases as compared with currently utilized IV therapy. Rather than producing a sudden and rapid high concentration in blood levels as is usually the case with an IV infusion, absorption of the active agent through the gut wall (promoted by the enhancing agents), provides a more gradual appearance in the blood levels and a stable, steady-state maintenance of those levels at or close to the ideal range for a long period of time.

Pursuant to another aspect of the invention, combination oral dosage forms are provided which contain fixed quantities of at least one enhancing agent and at least one target agent. For example, such dosage forms can consist of tablets, capsules, caplets, gelcaps, pills, liquids, lozenges and any other conventional oral dosage forms containing as active ingredients an effective oral bioavailability

enhancing amount of an antitumor or anti-neoplastic agent, as well as suitable inactive ingredients. One such combination product includes from about 0.1 to about 20 mg/kg of one or more of cyclosporins A, D, C, F and G, dihydro CsA, dihydro CsC and acetyl CsA together with about 20 to about 1000 mg/m² (based on average patient body surface area), and preferably about 50-200 mg/m², of paclitaxel, docetaxel, other taxanes or paclitaxel or docetaxel derivatives such as paclitaxel 2'- MPM or docetaxel 2'- MPM.

The co-administration of enhancing agents with the target drugs promotes not only the oral bioavailability of those agents but also enables their use in the treatment of tumors at sites highly protected by MDR, e.g., the testes and the brain. Another aspect of the present invention is, thus, a method of delivering antitumor drugs to tumor sites protected by MDR through the oral co-administration of enhancing agents and the antitumor agents, making it possible to treat brain tumors such as glioblastoma multiforme.

Further advantages of the present invention are in the area of safety. Because of its physico-chemical properties, paclitaxel must be solubilized in a Cremophor/ethanol mixture and that vehicle may be responsible for at least some of the allergic-type reactions experienced by patients on paclitaxel therapy. Other solubilizing agents have been used but none have been as suitable as Cremophor/ethanol. Paclitaxel must be given slowly to patients, with medical personnel in a state of constant vigilance for severe hypersensitivity reactions. For standard intravenous regimens, pre-medication regimens of H-1 and H-2 blockers plus steroids are generally required. However, even when Cremophor/ethanol solubilization is not used, intravenous taxanes can still bring about severe reactions

following intravenous use. Thus, docetaxel administration is associated with anasarca and other reactions. Therapies with the potential to eliminate or diminish the need for pre-medication in these settings would be very valuable clinically.

The present invention, in one of its embodiments, provides a method of preventing or reducing hypersensitivity and allergic reactions in human patients receiving taxane therapy. The method comprises the oral administration of the taxane to the patients. Oral administration by the instantly disclosed method is much less likely than intravenous therapy to produce such adverse reactions. Indeed, we administered paclitaxel to human patients (see Examples 2 and 3) with no pre-medication (i.e., with H-1 or H-2 blockers or steroids), and no hypersensitivity reactions were observed while achieving therapeutic circulating levels.

Furthermore, paclitaxel use is associated with a variety of toxicities and side-effects. Two of the most noteworthy toxicities are neutropenia and neuropathy. A variety of clinical data have shown that it would be desirable to keep the circulating plasma concentrations within a certain "window" in order to maximize the anti-tumor activity and minimize the side effects, especially neutropenia. For many tumor types, it is believed that low, but long-term, exposure of tumor cells in the body results in better clinical results. Thus, plasma levels of about .03 micromolar would be expected to inhibit cancer-cell protein isoprenylation and levels of about 0.1 micromolar would be expected to block disassembly of microtubules. There are clinical data showing that constant intravenous administration over several days to achieve a "window" of about .05 to 0.1 micromolar in the circulation can minimize toxicities and cause tumor regressions, sometimes even in patients whose tumors did not respond to 3-hour

infusion regimens. The currently approved 3-hour infusion regimens of paclitaxel achieve peak plasma concentrations that greatly exceed these levels

The present invention also makes it possible to give paclitaxel in comparatively infrequent daily doses (e.g., about twice/day) and according to schedules that would otherwise not be possible or practical with the intravenous route. The use of the enhancer (e.g., cyclosporin A) promotes oral absorption of paclitaxel for the first dose and if a second paclitaxel dose is to be given later in the day, the use of additional cyclosporin A may not even be needed. Thus, paclitaxel could be given intermittently as single dose on a fixed schedule (weekly, biweekly, etc.) or chronically, over a period of consecutive days (e.g., 4 days) every 2-4 weeks with the goal of keeping the levels within a safe and effective "window".

The following examples illustrate various aspects of the invention and demonstrate the unexpected, very substantial increases in the oral absorption of paclitaxel achieved. These examples are not intended, however, to limit the invention in any way or to set forth specific enhancing or target agents, dosage ranges, testing procedures or other parameters which must be used exclusively to practice the invention.

EXAMPLE 1

Six (6) healthy Sprague Dawley rats, all weighing from 225-275 grams and approximately six to eight weeks old, received a single oral dose of paclitaxel at 9 mg/kg. Blood samples were collected from the tail vein of each rat at 0.5, 1, 2, 3, 4 and 6 hours after the paclitaxel dose. The individual samples were centrifuged and the serum was separated. For each time interval, the six samples were composited

to produce a single representative sample. All samples were assayed for unchanged paclitaxel by LC/MS with a lower limit of quantitation of 50 pg/ml.

The results of the study are graphically illustrated in the lower curve of FIG. 1, which indicates that the bioavailability of the orally administered paclitaxel in serum was less than 1%.

EXAMPLE 2

Ten (10) healthy Sprague Dawley rats with the same characteristics as those used in the study described in Example 1 were treated with 5 mg/kg of oral cyclosporin A followed 1 hour later with another 5 mg/kg dose of oral cyclosporin A and 9 mg/kg of oral paclitaxel.

Blood samples were collected from the tail vein of each rat at 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours after paclitaxel administration. After appropriate treatment of the samples and the creation of one composite sample for the group, the plasma from each sample was assayed for unchanged paclitaxel.

The results of this study are graphically illustrated in the upper curve of FIG. 1. It may be observed that the plasma levels of paclitaxel in this group of animals was several times higher during the first six hours than in the rats of Example 1 who received paclitaxel alone, that levels at or above the "target" therapeutic levels were maintained for (8) eight hours after dosing and that significant plasma levels were maintained throughout the 24-hour period.

EXAMPLE 3

A 71-year old man with prostate cancer for three years agreed to receive an oral dose of paclitaxel and an enhancer in the form of cyclosporin A. His body surface area was 2.04 square meters and his weight was approximately 84 kilograms.

After an overnight fast, he received two oral doses of cyclosporin A (Sandimmune 5 mg/kg) one hour apart. Just after the second dose, the patient drank a Cremophor/alcohol-based solution-dose of paclitaxel containing 180 mg dissolved in 120 ml of 5% dextrose in water, i.e., about 2.0 mg/kg of body weight or about 90 mg/m² of body area. Standard premedications, as one would use for short term infusions of taxanes, were not given. After drinking the solution, the patient remarked that the taste was unpleasant. He experienced some loose stools for a few hours. He also reported some flushing several hours after dosing which may have been related to the temporary cessation of his anti-hypertensive medication. His clinical course was otherwise unremarkable.

Plasma samples were obtained at frequent intervals following the administration of paclitaxel and were assayed by LC/MS/MS. The plasma level results over time are shown in FIG. 2. Peak was reached about 4 hours post dosing and levels above 0.07 micromolar were achieved from about one to five hours. Levels comparable to those found in breast cancer patients receiving 96-hour intravenous infusions of paclitaxel (0.05 micromolar) were present for about 10-12 hours (Seidman et al., J. Clin. Oncol., 14:1877, 1996).

EXAMPLE 4

A 75-year old man with prostate cancer for several years received an oral dose of paclitaxel and cyclosporin A. His body surface area was 1.82 square meters and his weight was approximately 72 kilograms. After an overnight fast, he received the same regimen of cyclosporin A (Sandimmune 5 mg/kg) and oral paclitaxel (180 mg) as the patient in Example 1, which equaled about 2.5 mg/kg or about 100 mg/m² of paclitaxel in this patient. Again, standard premedications, as one would use for

short- term infusions of taxanes, were not given. After drinking the solution, the patient remarked that the taste was unpleasant. He experienced some loose stools for a few hours. He also had a modest decline in blood pressure after dosing which may have been related to a vasovagal reaction secondary to his fasting state and
5 blood draws. As a precaution the patient received about 100 ml of saline intravenously. After eating lunch he felt much better and the remainder of his clinical course was otherwise unremarkable.

Plasma samples were obtained at frequent intervals following the administration of paclitaxel and were assayed by LC/MS/MS. The plasma level results
10 over time are shown in FIG. 3. The peak level was almost 0.3 micromolar and occurred at 4 hours post dosing. Levels above 0.07 micromolar were achieved from about one to ten hours. Levels comparable to those found in breast cancer patients receiving 96-hour intravenous infusions of paclitaxel were present for about 12-15 hours.

15 As noted previously, FIG. 4 represents a composite of the paclitaxel concentration levels determined over time in rats (upper curve from FIG. 1) and in humans (curves from FIGS. 2 and 3) administered oral paclitaxel following two doses of oral cyclosporin spaced one hour apart, in accordance with the present invention. It will be observed that the concentration levels achieved in humans not merely
20 confirm the efficacy of the present invention in making paclitaxel orally bioavailable for the first time, but they exceed the concentration levels achieved in the rat model. These results are unexpected and surprising and, until we demonstrated the clinical efficacy of the subject method in human beings, it could not have been predicted

based on any prior art disclosures regarding cyclosporins or other potential enhancing agents or regarding paclitaxel, its derivatives, analogs and prodrugs or other taxanes.

It has thus been shown that there are provided methods which achieve the various objects of the invention and which are well adapted to meet the conditions of practical use.

As various possible embodiments might be made of the above invention, and as various changes might be made in the embodiments set forth above, it is to be understood that all matters herein described are to be interpreted as illustrative and not in a limiting sense.

What is claimed as new and desired to be protected by Letters Patent is set forth in the following claims.

WE CLAIM:

1. Use of an oral bioavailability enhancing agent in the preparation of a medicament for preventing or reducing hypersensitivity or allergic reactions in a patient undergoing taxane therapy for a taxane-responsive disease condition, wherein a taxane and an oral bioavailability enhancing agent are capable of being orally co-administered to the patient, without prior administration of medication to prevent the hypersensitivity or allergic reactions, and wherein the taxane reaches therapeutic blood or plasma levels in said patient.
2. The use of claim 1, wherein the taxane is selected from the group consisting of paclitaxel and analogs, derivatives and prodrugs thereof.
3. The use of claim 1, wherein the taxane is an analog of paclitaxel.
4. The use of claim 3, wherein the analog of paclitaxel is docetaxel.
5. The use of claim 1, wherein the enhancing agent is capable of being administered either
 - a) about 0.5-72 hours before,
 - b) less than 0.5 hour before, together with or less than 0.5 hour after, or
 - c) both about 0.5-72 hours before and again less than 0.5 hour before, together with or less than 0.5 hour after, the administration of the taxane.
6. The use of claim 1, wherein the taxane and the enhancing agent are capable of being administered in separate oral dosage forms.
7. The use of claim 1, wherein the taxane and the enhancing agent are capable of being administered together in a combination oral dosage form.
8. The use of claim 1 or claim 5, wherein the taxane is paclitaxel.
9. The use of claim 8, wherein the enhancing agent is cyclosporin A.

10. The use of claim 9, wherein the cyclosporin A is capable of being administered in an amount of from about 0.1 to 20 mg/kg of patient body weight.
11. The use of claim 10, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered once a week.
12. The use of claim 11, wherein the paclitaxel is capable of being administered in a divided dose.
13. The use of claim 1 or claim 5, wherein the taxane is docetaxel.
14. The use of claim 13, wherein the enhancing agent is cyclosporin A.
15. The use of claim 14, wherein the cyclosporin A is capable of being administered in an amount of from about 0.1 to 20 mg/kg of patient body weight.
16. The use of claim 1, wherein two or more doses of the taxane are capable of being administered after a single dose of the enhancing agent.
17. The use of claim 1, wherein the patient is capable of being administered about 20-1,000 mg/m² of the taxane based on patient body surface area.
18. The use of claim 17, wherein the patient is capable of being administered about 50-200 mg/m² of the taxane.
19. The use of claim 1, wherein the taxane comprises about 2-30 mg/kg of paclitaxel based on patient body weight.
20. The use of claim 19, wherein the taxane comprises about 2-6 mg/kg of paclitaxel.
21. The use of claim 1, wherein the patient is capable of being administered about 0.1 to about 20 mg/kg of the enhancing agent based on patient body weight.

22. The use of claim 1, wherein the taxane, the enhancing agent or both is each capable of being administered in a dosage form selected from the group consisting of tablets, softgel capsules, hardgel capsules, caplets, gelcaps, pills, lozenges, powders, micronized particles, osmotic delivery systems, and liquid solutions, suspensions and elixirs.

23. The use of claim 1, wherein the taxane is capable of being administered is paclitaxel in a formulation further comprising a polyethoxylated castor oil, alcohol or polyoxyethylated sorbitan mono-oleate.

24. The use of claim 1, wherein the disease condition is a cancer, tumor, malignancy, uncontrolled tissue or cellular proliferation secondary to tissue injury, or an inflammatory disease.

25. The use of claim 1, wherein the disease condition is selected from the group consisting of pancreatic cancer, prostate cancer, hepatocellular carcinoma, liver metastases, gastrointestinal tract cancers, Kaposi's sarcoma, polycystic kidney disease and malaria.

26. The use of claim 1, wherein the disease condition is selected from the group consisting of gastrointestinal tract cancers and lung cancers.

27. The use of claim 1, wherein the disease condition is cancer.

28. The use of claim 27, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.

29. The use of claim 28, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.

30. The use of claim 29, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered about once per week.

31. The use of claim 30, wherein the paclitaxel is capable of being administered in a divided dose.

32. The use of claim 27, wherein the taxane is docetaxel.
33. The use of claim 32, wherein the bioavailability enhancing agent is cyclosporin A.
34. The use of claim 33, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.
35. The use of claim 1, wherein the disease condition is lung cancer.
36. The use of claim 35, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.
37. The use of claim 36, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.
38. The use of claim 37, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered about once per week.
39. The use of claim 38, wherein the paclitaxel is capable of being administered in a divided dose.
40. The use of claim 35, wherein the taxane is docetaxel.
41. The use of claim 40, wherein the bioavailability enhancing agent is cyclosporin A.
42. The use of claim 41, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.
43. The use of claim 1, wherein the disease condition is a cancer of the gastrointestinal tract.

44. The use of claim 43, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.
45. The use of claim 44, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.
46. The use of claim 45, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered about once per week.
47. The use of claim 46, wherein the paclitaxel is capable of being administered in a divided dose.
48. The use of claim 43, wherein the taxane is docetaxel.
49. The use of claim 48, wherein the bioavailability enhancing agent is cyclosporin A.
50. The use of claim 49, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.
51. The use of claim 1, wherein the taxane is a derivative, an analog of a prodrug of paclitaxel or docetaxel.
52. The use of claim 1, wherein the taxane is paclitaxel 2'-MPM or docetaxel 2'-MPM.
53. The use of claim 1, wherein the bioavailability enhancing agent is a cyclosporin.
54. The use of claim 53 wherein the cyclosporin is selected from the group consisting of cyclosporins A through Z, (Me-Ile-4)-cyclosporin, dihydro cyclosporin A, dihydro cyclosporin C and acetyl cyclosporin A, and related oligopeptides produced by species of the genus *Tolypocladium*.

55. The use of claim 53, wherein the cyclosporin is selected from the group consisting of cyclosporin A, cyclosporin C, cyclosporin D, cyclosporin F, dihydro cyclosporin A, dihydro cyclosporin C and acetyl cyclosporin A.
56. The use of claim 53, wherein the cyclosporin is cyclosporin A.
57. The use of claim 1, wherein the taxane is capable of being subsequently administered without co-administration of the bioavailability enhancing agent.
58. The use of claim 29, wherein the paclitaxel is capable of being subsequently administered without co-administration of the cyclosporin A.
59. The use of claim 1, wherein the disease condition is ovarian cancer.
60. The use of claim 59, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.
61. The use of claim 60, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.
62. The use of claim 61, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered about once per week.
63. The use of claim 62, wherein the paclitaxel is capable of being administered in a divided dose.
64. The use of claim 59, wherein the taxane is docetaxel.
65. The use of claim 64, wherein the bioavailability enhancing agent is cyclosporin A.
66. The use of claim 65, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.
67. The use of claim 1, wherein the disease condition is breast cancer.

68. The use of claim 67, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.
69. The use of claim 68, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.
70. The use of claim 69, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered about once per week.
71. The use of claim 70, wherein the paclitaxel is capable of being administered in a divided dose.
72. The use of claim 67, wherein the taxane is docetaxel.
73. The use of claim 72, wherein the bioavailability enhancing agent is cyclosporin A.
74. The use of claim 73, wherein from about 0.1 to about 20 mg/kg of cyclosporin A is capable of being orally administered to the patient.
75. Use of an oral bioavailability enhancing agent for the prevention or reduction of hypersensitivity or allergic reactions in a patient undergoing taxane therapy for a taxane-responsive disease condition, wherein a taxane and an oral bioavailability enhancing agent are capable of being orally co-administered without prior administration of medication to prevent the hypersensitivity or allergic reactions, and wherein the taxane reaches therapeutic blood or plasma levels in said patient.
76. The use of claim 75, wherein the taxane is selected from the group consisting of paclitaxel and analogs, derivatives and prodrugs thereof.
77. The use of claim 75, wherein the taxane is an analog of paclitaxel.
78. The use of claim 77, wherein the analog of paclitaxel is docetaxel.

79. The use of claim 75, wherein the enhancing agent is capable of being administered either
- a) about 0.5-72 hours before,
 - b) less than 0.5 hour before, together with or less than 0.5 hour after,
- or
- c) both about 0.5-72 hours before and again less than 0.5 hour before, together with or less than 0.5 hours after, the administration of the taxane.
80. The use of claim 75, wherein the taxane and the enhancing agent are capable of being administered in separate oral dosage forms.
81. The use of claim 75, wherein the taxane and the enhancing agent are capable of being administered together in a combination oral dosage form.
82. The use of claim 75 or claim 81 wherein the taxane is paclitaxel.
83. The use of claim 82, wherein the enhancing agent is cyclosporin A.
84. The use of claim 83, wherein the cyclosporin A is capable of being administered in an amount of from about 0.1 to 20 mg/kg of patient body weight.
85. The use of claim 84, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered once a week.
86. The use of claim 85, wherein the paclitaxel is capable of being administered in a divided dose.
87. The use of claim 75 or claim 79, wherein the taxane is docetaxel.
88. The use of claim 87, wherein the enhancing agent is cyclosporin A.
89. The use of claim 88, wherein the cyclosporin A is capable of being administered in an amount of from about 0.1 to 20 mg/kg of patient body weight.

90. The use of claim 75, wherein two or more doses of the taxane are capable of being administered after a single dose of the enhancing agent.
91. The use of claim 75, wherein the dose of the taxane is capable of being administered at about 20-1,000 mg/m² based on patient body surface area.
92. The use of claim 91, wherein about 50-200 mg/m² of the taxane is capable of being administered.
93. The use of claim 75, wherein the taxane comprises about 2-30 mg/kg of paclitaxel based on patient body weight.
94. The use of claim 93, wherein the taxane comprises about 2-6 mg/kg of paclitaxel.
95. The use of claim 75 wherein the enhancing agent is capable of being administered at about 0.1 to about 20 mg/kg based on patient body weight.
96. The use of claim 75, wherein the taxane, the enhancing agent or both is each capable of being administered in a dosage form selected from the group consisting of tablets, softgel capsules, hardgel capsules, caplets, gelcaps, pills, lozenges, powders, micronized particles, osmotic delivery systems, and liquid solutions, suspensions and elixirs.
97. The use of claim 75, wherein the taxane is paclitaxel in a formulation further comprising a polyethoxylated castor oil, alcohol or polyoxyethylated sorbitan mono-oleate.
98. The use of claim 75, wherein the disease condition is a cancer, tumor, malignancy, uncontrolled tissue or cellular proliferation secondary to tissue injury, or an inflammatory disease.
99. The use of claim 75, wherein the disease condition is selected from the group consisting of pancreatic cancer, prostate cancer, hepatocellular carcinoma, liver

metastases, gastrointestinal tract cancers, Kaposi's sarcoma, polycystic kidney disease and malaria.

100. The use of claim 75, wherein the disease condition is selected from the group consisting of gastrointestinal tract cancers and lung cancers.

101. The use of claim 75, wherein the disease condition is cancer.

102. The use of claim 101, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.

103. The use of claim 102, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered.

104. The use of claim 103, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered about once per week.

105. The use of claim 104, wherein the paclitaxel is capable of being administered in a divided dose.

106. The use of claim 101, wherein the taxane is docetaxel.

107. The use of claim 106, wherein the bioavailability enhancing agent is cyclosporin A.

108. The use of claim 107, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered.

109. The use of claim 75, wherein the disease condition is lung cancer.

110. The use of claim 109, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.

111. The use of claim 110, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered.

112. The use of claim 111, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered about once per week.

113. The use of claim 112, wherein the paclitaxel is capable of being administered in a divided dose.

114. The use of claim 109, wherein the taxane is docetaxel.

115. The use of claim 114, wherein the bioavailability enhancing agent is cyclosporin A.

116. The use of claim 115, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered.

117. The use of claim 75, wherein the disease condition is a cancer of the gastrointestinal tract.

118. The use of claim 117, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.

119. The use of claim 118, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered.

120. The use of claim 119, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered about once per week.

121. The use of claim 120, wherein the paclitaxel is capable of being administered in a divided dose.

122. The use of claim 117, wherein the taxane is docetaxel.

123. The use of claim 122, wherein the bioavailability enhancing agent is cyclosporin A.

124. The use of claim 123, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered.

125. The use of claim 75, wherein the taxane is a derivative, an analog of a prodrug of paclitaxel or docetaxel.

126. The use of claim 75, wherein the taxane is paclitaxel 2'-MPM or docetaxel 2'-MPM.

127. The use of claim 75, wherein the bioavailability enhancing agent is a cyclosporin.

128. The use of claim 127, wherein the cyclosporin is selected from the group consisting of cyclosporins A through Z, (Me-Ile-4)-cyclosporin, dihydro cyclosporin A, dihydro cyclosporin C and acetyl cyclosporin A, and related oligopeptides produced by species of the genus *Tolypocladium*.

129. The use of claim 127, wherein the cyclosporin is selected from the group consisting of cyclosporin A, cyclosporin C, cyclosporin D, cyclosporin F, dihydro cyclosporin A, dihydro cyclosporin C and acetyl cyclosporin A.

130. The use of claim 127, wherein the cyclosporin is cyclosporin A.

131. The use of claim 75, wherein the taxane is capable of being subsequently administered without co-administration of the bioavailability enhancing agent.

132. The use of claim 103, wherein the paclitaxel is capable of being subsequently administered without co-administration of the cyclosporin A.

133. The use of claim 75, wherein the disease condition is ovarian cancer.

134. The use of claim 133, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.

135. The use of claim 134, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered.

136. The use of claim 135, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered.

137. The use of claim 136, wherein the paclitaxel is capable of being administered in a divided dose.

138. The use of claim 133, wherein the taxane is docetaxel.

139. The use of claim 138, wherein the bioavailability enhancing agent is cyclosporin A.

140. The use of claim 139, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered.

141. The use of claim 75, wherein the disease condition is breast cancer.

142. The use of claim 141, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.

143. The use of claim 142, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered.

144. The use of claim 143, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered about once per week.

145. The use of claim 144, wherein the paclitaxel is capable of being administered in a divided dose.

146. The use of claim 141, wherein the taxane is docetaxel.

147. The use of claim 146, wherein the bioavailability enhancing agent is cyclosporin A.

148. The use of claim 147, wherein from about 0.1 to about 20 mg/kg of cyclosporin A is capable of being orally administered.

149. Use of a taxane in the preparation of a medicament for preventing or reducing hypersensitivity or allergic reactions in a patient wherein an oral bioavailability enhancing agent and the taxane are capable of being orally co-administered to the patient without prior administration of medication to prevent the hypersensitivity or allergic reactions, and wherein the taxane reaches therapeutic blood or plasma levels.

150. The use of claim 149, wherein the taxane is selected from the group consisting of paclitaxel and analogs, derivatives and prodrugs thereof.

151. The use of claim 149, wherein the taxane is an analog of paclitaxel.

152. The use of claim 151, wherein the analog of paclitaxel is docetaxel.

153. The use of claim 149, wherein the enhancing agent is capable of being administered either

- a) about 0.5-72 hours before,
- b) less than 0.5 hour before, together with or less than 0.5 hour after, or
- c) both about 0.5-72 hours before and again less than 0.5 hour before,

together with or less than 0.5 hour after, the administration of the taxane.

154. The use of claim 149, wherein the taxane and the enhancing agent are capable of being administered in separate oral dosage forms.

155. The use of claim 149, wherein the taxane and the enhancing agent are capable of being administered together in a combination oral dosage form.

156. The use of claim 149 or claim 153, wherein the taxane is paclitaxel.

157. The use of claim 156, wherein the enhancing agent is cyclosporin A.

158. The use of claim 157, wherein the cyclosporin A is capable of being administered in an amount of from about 0.1 to 20 mg/kg of patient body weight.
159. The use of claim 158, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered once a week.
160. The use of claim 159, wherein the paclitaxel is capable of being administered in a divided dose.
161. The use of claim 149 or claim 153, wherein the taxane is docetaxel.
162. The use of claim 161, wherein the enhancing agent is cyclosporin A.
163. The use of claim 162, wherein the cyclosporin A is capable of being administered in an amount of from about 0.1 to 20 mg/kg of patient body weight.
164. The use of claim 149, wherein two or more doses of the taxane are capable of being administered after a single dose of the enhancing agent.
165. The use of claim 149, wherein the patient is capable of being administered about 20-1,000 mg/m² of the taxane based on patient body surface area.
166. The use of claim 165, wherein the patient is capable of being administered about 50-200 mg/m² of the taxane.
167. The use of claim 149, wherein the taxane comprises about 2-30 mg/kg of paclitaxel based on patient body weight.
168. The use of claim 167, wherein the taxane comprises about 2-6 mg/kg of paclitaxel.
169. The use of claim 149, wherein the patient is capable of being administered about 0.1 to about 20 mg/kg of the enhancing agent based on patient body weight.

170. The use of claim 149, wherein the taxane, the enhancing agent or both is each capable of being administered in a dosage form selected from the group consisting of tablets, softgel capsules, hardgel capsules, caplets, gelcaps, pills, lozenges, powders, micronized particles, osmotic delivery systems, and liquid solutions, suspensions and elixirs.

171. The use of claim 149, wherein the taxane is capable of being administered is paclitaxel in a formulation further comprising a polyethoxylated castor oil, alcohol or polyoxyethylated sorbitan mono-oleate.

172. The use of claim 149, wherein the disease condition is a cancer, tumor, malignancy, uncontrolled tissue or cellular proliferation secondary to tissue injury, or an inflammatory disease.

173. The use of claim 149, wherein the disease condition is selected from the group consisting of pancreatic cancer, prostate cancer, hepatocellular carcinoma, liver metastases, gastrointestinal tract cancers, Kaposi's sarcoma, polycystic kidney disease and malaria.

174. The use of claim 149, wherein the disease condition is selected from the group consisting of gastrointestinal tract cancers and lung cancers.

175. The use of claim 149, wherein the disease condition is cancer.

176. The use of claim 175, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.

177. The use of claim 176, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.

178. The use of claim 177, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered about once per week.

179. The use of claim 178, wherein the paclitaxel is capable of being administered in a divided dose.

180. The use of claim 175 wherein the taxane is docetaxel.
181. The use of claim 180, wherein the bioavailability enhancing agent is cyclosporin A.
182. The use of claim 181, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.
183. The use of claim 149, wherein the disease condition is lung cancer.
184. The use of claim 183, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.
185. The use of claim 184, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.
186. The use of claim 185, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered about once per week.
187. The use of claim 186, wherein the paclitaxel is capable of being administered in a divided dose.
188. The use of claim 183, wherein the taxane is docetaxel.
189. The use of claim 188, wherein the bioavailability enhancing agent is cyclosporin A.
190. The use of claim 189, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.
191. The use of claim 149, wherein the disease condition is a cancer of the gastrointestinal tract.

192. The use of claim 191, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.

193. The use of claim 192 wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.

194. The use of claim 193, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered about once per week.

195. The use of claim 194, wherein the paclitaxel is capable of being administered in a divided dose.

196. The use of claim 191, wherein the taxane is docetaxel.

197. The use of claim 196, wherein the bioavailability enhancing agent is cyclosporin A.

198. The use of claim 197, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.

199. The use of claim 149, wherein the taxane is a derivative, an analog of a prodrug of paclitaxel or docetaxel.

200. The use of claim 149, wherein the taxane is paclitaxel 2'-MPM or docetaxel 2'-MPM.

201. The use of claim 149, wherein the bioavailability enhancing agent is a cyclosporin.

202. The use of claim 201 wherein the cyclosporin is selected from the group consisting of cyclosporins A through Z, (Me-Ile-4)-cyclosporin, dihydro cyclosporin A, dihydro cyclosporin C and acetyl cyclosporin A, and related oligopeptides produced by species of the genus *Tolypocladium*.

203. The use of claim 201, wherein the cyclosporin is selected from the group consisting of cyclosporin A, cyclosporin C, cyclosporin D, cyclosporin F, dihydro cyclosporin A, dihydro cyclosporin C and acetyl cyclosporin A.

204. The use of claim 201, wherein the cyclosporin is cyclosporin A.

205. The use of claim 149, wherein the taxane is capable of being subsequently administered without co-administration of the bioavailability enhancing agent.

206. The use of claim 177, wherein the paclitaxel is capable of being subsequently administered without co-administration of the cyclosporin A.

207. The use of claim 149, wherein the disease condition is ovarian cancer.

208. The use of claim 207, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.

209. The use of claim 208, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.

210. The use of claim 209, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered about once per week.

211. The use of claim 210 wherein the paclitaxel is capable of being administered in a divided dose.

212. The use of claim 207, wherein the taxane is docetaxel.

213. The use of claim 212, wherein the bioavailability enhancing agent is cyclosporin A.

214. The use of claim 213, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.

215. The use of claim 149, wherein the disease condition is breast cancer.

216. The use of claim 215, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.

217. The use of claim 216, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.

218. The use of claim 217, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered about once per week.

219. The use of claim 218, wherein the paclitaxel is capable of being administered in a divided dose.

220. The use of claim 215, wherein the taxane is docetaxel.

221. The use of claim 220, wherein the bioavailability enhancing agent is cyclosporin A.

222. The use of claim 221 wherein from about 0.1 to about 20 mg/kg of cyclosporin A is capable of being orally administered to the patient.

223. The use of a taxane in a patient wherein an oral bioavailability enhancing agent and the taxane are capable of being orally co-administered to the patient without prior administration of medication to prevent the hypersensitivity or allergic reactions, and wherein the taxane reaches therapeutic blood or plasma levels.

224. The use of claim 223 wherein the taxane is selected from the group consisting of paclitaxel and analogs, derivatives and prodrugs thereof.

225. The use of claim 223, wherein the taxane is an analog of paclitaxel.

226. The use of claim 225, wherein the analog of paclitaxel is docetaxel.

227. The use of claim 223, wherein the enhancing agent is capable of being administered either

- a) about 0.5-72 hours before,
 - b) less than 0.5 hour before, together with or less than 0.5 hour after, or
 - c) both about 0.5-72 hours before and again less than 0.5 hour before,
- together with or less than 0.5 hour after, the administration of the taxane.

228. The use of claim 223, wherein the taxane and the enhancing agent are capable of being administered in separate oral dosage forms.

229. The use of claim 223, wherein the taxane and the enhancing agent are capable of being administered together in a combination oral dosage form.

230. The use of claim 223 or claim 227, wherein the taxane is paclitaxel.

231. The use of claim 230, wherein the enhancing agent is cyclosporin A.

232. The use of claim 231, wherein the cyclosporin A is capable of being administered in an amount of from about 0.1 to 20 mg/kg of patient body weight.

233. The use of claim 232, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered once a week.

234. The use of claim 233, wherein the paclitaxel is capable of being administered in a divided dose.

235. The use of claim 223 or claim 227, wherein the taxane is docetaxel.

236. The use of claim 235, wherein the enhancing agent is cyclosporin A.

237. The use of claim 236, wherein the cyclosporin A is capable of being administered in an amount of from about 0.1 to 20 mg/kg of patient body weight.

238. The use of claim 223, wherein two or more doses of the taxane are capable of being administered after a single dose of the enhancing agent.

239. The use of claim 223, wherein the patient is capable of being administered about 20-1,000 mg/m² of the taxane based on patient body surface area.

240. The use of claim 239, wherein the patient is capable of being administered about 50-200 mg/m² of the taxane.

241. The use of claim 223, wherein the taxane comprises about 2-30 mg/kg of paclitaxel based on patient body weight.

242. The use of claim 241, wherein the taxane comprises about 2-6 mg/kg of paclitaxel.

243. The use of claim 223, wherein the patient is capable of being administered about 0.1 to about 20 mg/kg of the enhancing agent based on patient body weight.

244. The use of claim 223, wherein the taxane, the enhancing agent or both is each capable of being administered in a dosage form selected from the group consisting of tablets, softgel capsules, hardgel capsules, caplets, gelcaps, pills, lozenges, powders, micronized particles, osmotic delivery systems, and liquid solutions, suspensions and elixirs.

245. The use of claim 223, wherein the taxane is capable of being administered is paclitaxel in a formulation further comprising a polyethoxylated castor oil, alcohol or polyoxyethylated sorbitan mono-oleate.

246. The use of claim 223, wherein the disease condition is a cancer, tumor, malignancy, uncontrolled tissue or cellular proliferation secondary to tissue injury, or an inflammatory disease.

247. The use of claim 223, wherein the disease condition is selected from the group consisting of pancreatic cancer, prostate cancer, hepatocellular carcinoma, liver metastases, gastrointestinal tract cancers, Kaposi's sarcoma, polycystic kidney disease and malaria.

248. The use of claim 223, wherein the disease condition is selected from the group consisting of gastrointestinal tract cancers and lung cancers.
249. The use of claim 223, wherein the disease condition is cancer.
250. The use of claim 249, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.
251. The use of claim 250, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.
252. The use of claim 251, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered about once per week.
253. The use of claim 252, wherein the paclitaxel is capable of being administered in a divided dose.
254. The use of claim 249 wherein the taxane is docetaxel.
255. The use of claim 254, wherein the bioavailability enhancing agent is cyclosporin A.
256. The use of claim 255, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.
257. The use of claim 223, wherein the disease condition is lung cancer.
258. The use of claim 257, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.
259. The use of claim 258, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.
260. The use of claim 259, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered about once per week.

261. The use of claim 260, wherein the paclitaxel is capable of being administered in a divided dose.
262. The use of claim 257, wherein the taxane is docetaxel.
263. The use of claim 262, wherein the bioavailability enhancing agent is cyclosporin A.
264. The use of claim 263, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.
265. The use of claim 223, wherein the disease condition is a cancer of the gastrointestinal tract.
266. The use of claim 265, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.
267. The use of claim 266 wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.
268. The use of claim 267 wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered about once per week.
269. The use of claim 268, wherein the paclitaxel is capable of being administered in a divided dose.
270. The use of claim 265, wherein the taxane is docetaxel.
271. The use of claim 270, wherein the bioavailability enhancing agent is cyclosporin A.
272. The use of claim 271, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.

273. The use of claim 223, wherein the taxane is a derivative, an analog of a prodrug of paclitaxel or docetaxel.
274. The use of claim 223, wherein the taxane is paclitaxel 2'-MPM or docetaxel 2'-MPM.
275. The use of claim 223, wherein the bioavailability enhancing agent is a cyclosporin.
276. The use of claim 275 wherein the cyclosporin is selected from the group consisting of cyclosporins A through Z, (Me-Ile-4)-cyclosporin, dihydro cyclosporin A, dihydro cyclosporin C and acetyl cyclosporin A, and related oligopeptides produced by species of the genus *Tolypocladium*.
277. The use of claim 275 wherein the cyclosporin is selected from the group consisting of cyclosporin A, cyclosporin C, cyclosporin D, cyclosporin F, dihydro cyclosporin A, dihydro cyclosporin C and acetyl cyclosporin A.
278. The use of claim 275, wherein the cyclosporin is cyclosporin A.
279. The use of claim 223, wherein the taxane is capable of being subsequently administered without co-administration of the bioavailability enhancing agent.
280. The use of claim 251, wherein the paclitaxel is capable of being subsequently administered without co-administration of the cyclosporin A.
281. The use of claim 223, wherein the disease condition is ovarian cancer.
282. The use of claim 281, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.
283. The use of claim 282, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.

284. The use of claim 283, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered about once per week.

285. The use of claim 284 wherein the paclitaxel is capable of being administered in a divided dose.

286. The use of claim 281, wherein the taxane is docetaxel.

287. The use of claim 286, wherein the bioavailability enhancing agent is cyclosporin A.

288. The use of claim 287, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.

289. The use of claim 223, wherein the disease condition is breast cancer.

290. The use of claim 289, wherein the taxane is paclitaxel and the bioavailability enhancing agent is cyclosporin A.

291. The use of claim 290, wherein from about 0.1 to about 20 mg/kg of cyclosporin A are capable of being orally administered to the patient.

292. The use of claim 291, wherein the paclitaxel and the cyclosporin A are capable of being orally co-administered about once per week.

293. The use of claim 292, wherein the paclitaxel is capable of being administered in a divided dose.

294. The use of claim 289, wherein the taxane is docetaxel.

295. The use of claim 294, wherein the bioavailability enhancing agent is cyclosporin A.

296. The use of claim 295 wherein from about 0.1 to about 20 mg/kg of cyclosporin A is capable of being orally administered to the patient.

297. Use of a taxane and an oral bioavailability-enhancing agent for the manufacture of a medicament for oral co-administration of the taxane and the oral bioavailability-enhancing agent to a patient to provide the patient with taxane therapy for the treatment of a taxane-responsive disease, wherein the patient is a human to whom there has been no prior administration of medication to prevent hypersensitivity or allergic reactions to the taxane therapy.

298. Use as claimed in claim 297, wherein the taxane is for oral administration to the patient in a liquid preparation which includes the taxane in a vehicle comprising a polyethoxylated castor oil, alcohol and/or a polyethoxylated sorbitan mono-oleate.

299. Use as claimed in claim 298, wherein the vehicle comprises an alcohol.

300. Use as claimed in any one of claims 297 to 299, wherein the taxane is paclitaxel.

301. Use as claimed in any one of claims 297 to 299, wherein the taxane is docetaxel.


302. Use as claimed in any one of claims 297 to 301, wherein the oral bioavailability-enhancing agent is selected from cyclosporins A through Z, (Me-Ile-4)-cyclosporin, dihydro cyclosporin A, dihydro cyclosporin C and acetyl cyclosporin A.

303. Use as claimed in claim 302, wherein the oral bioavailability-enhancing agent is cyclosporin A.


304. Use as claimed in any one of claims 297 to 303, wherein the taxane and the oral bioavailability-enhancing agent are for administration in separate oral dosage forms.

305. Use as claimed in any one of claims 297 to 304, wherein the taxane-responsive disease is selected from cancers, tumours, Kaposi's sarcoma, malignancies, uncontrolled tissue or cellular proliferation secondary to tissue injury, polycystic kidney disease and malaria.

306. Use as claimed in claim 305, wherein the taxane-responsive disease is selected from liver cancers, gastrointestinal cancers and lung cancers.




2/4



3/4

FIG. 3



4/4

